Novartis Vs Roche

The US Food and Drug Administration granted priority review for risdiplam, an oral medicine for those with the potentially deadly muscle-wasting disorder

Novartis's mix of Tafinlar and Mekinist slashed the risk of melanoma returning or death by 53%